HUMALOG (KWIKPEN) SOLUTION

Ülke: Kanada

Dil: İngilizce

Kaynak: Health Canada

Aktif bileşen:

INSULIN LISPRO

Mevcut itibaren:

ELI LILLY CANADA INC

ATC kodu:

A10AB04

INN (International Adı):

INSULIN LISPRO

Doz:

100UNIT

Farmasötik formu:

SOLUTION

Kompozisyon:

INSULIN LISPRO 100UNIT

Uygulama yolu:

INTRAMUSCULAR

Paketteki üniteler:

15G/50G

Reçete türü:

Schedule D

Terapötik alanı:

INSULINS

Ürün özeti:

Active ingredient group (AIG) number: 0131614001; AHFS:

Yetkilendirme durumu:

MARKETED

Yetkilendirme tarihi:

2013-08-14

Ürün özellikleri

_HUMALOG, HUMALOG 200 units/mL KwikPen, HUMALOG MIX25, HUMALOG MIX50 _
_Page 1 of 63 _
_ _
PRODUCT MONOGRAPH
HUMALOG
®
(insulin
lispro injection)
Solution
for Injection, 100 units/mL, Lilly Standard
ATC Code: A10AB04
fast-acting
HUMALOG
®
200 UNITS/ML KWIKPEN
®
(insulin
lispro injection)
Solution
for Injection, 200 units/mL, Lilly Standard
ATC Code: A10AB04
fast-acting
HUMALOG
® MIX25
®
(25% insulin
lispro injection,
75% insulin
lispro protamine suspension)
Suspension for Injection, 100 units/mL, Lilly Standard
ATC Code: A10AD04
intermediate- or long-acting combined with fast-acting
HUMALOG MIX50
®
(50% insulin
lispro injection,
50% insulin
lispro protamine suspension)
Suspension for Injection, 100 units/mL, Lilly Standard
ATC Code: A10AD04
intermediate- or long-acting combined with fast-acting
THERAPEUTIC CLASSIFICATION
Anti-Diabetic Agent
©Eli Lilly Canada Inc.
Exchange Tower
130 King Street West, Suite 900
P.O. Box 73
Toronto, Ontario
M5X 1B1
SUBMISSION CONTROL NO: 245846
DATE OF INITIAL APPROVAL:
October 8, 1996
DATE OF REVISION:
April 12, 2021
_HUMALOG, HUMALOG 200 units/mL KwikPen, HUMALOG MIX25, HUMALOG MIX50 _
_Page 2 of 63 _
_ _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
..................................................... 3
SUMMARY PRODUCT INFORMATION
....................................................................3
INDICATIONS AND CLINICAL USE
.........................................................................3
CONTRAINDICATIONS
.............................................................................................4
WARNINGS AND PRECAUTIONS
.............................................................................5
ADVERSE
REACTIONS............................................................................................
11
DRUG INTERACTIONS
............................................................................................
12
DOSAGE AND ADMINISTRATION
.........................................................................
13
OVERDOSAGE
...........